Literature DB >> 3388031

Isolation and characterization of a novel protein (X-ORF product) from SIV and HIV-2.

L E Henderson1, R C Sowder, T D Copeland, R E Benveniste, S Oroszlan.   

Abstract

A protein designated p14 was purified from a simian immunodeficiency virus (SIVMne) and was shown by amino acid sequence analysis to be nearly identical to the predicted translational product of a unique open reading frame (X-ORF) in the nucleotide sequences of SIVmac and human immunodeficiency virus type 2 (HIV-2). Thus the X-ORF is proven to be a new retroviral gene. The p14 is present in SIVMne in molar amounts equivalent to those of the gag proteins. This is the first example of a retrovirus that contains a substantial quantity of a viral protein that is not a product of the gag, pro, pol, or env genes. SIV p14 and its homolog in HIV-2 may function as nucleic acid binding proteins since purified p14 binds to single-stranded nucleic acids in vitro. Antisera to the purified protein detected p14 in SIVMne, SIVmac, and a homologous protein (16 kilodaltons) in HIV-2 but did not react with HIV-1. Diagnostic procedures based on this novel protein will distinguish between HIV-1 and HIV-2.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3388031     DOI: 10.1126/science.3388031

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  55 in total

1.  Interaction of human immunodeficiency virus type 2 Vpx and invariant chain.

Authors:  H A Pancio; N Vander Heyden; K Kosuri; P Cresswell; L Ratner
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Functional role of residues corresponding to helical domain II (amino acids 35 to 46) of human immunodeficiency virus type 1 Vpr.

Authors:  S P Singh; B Tomkowicz; D Lai; M Cartas; S Mahalingam; V S Kalyanaraman; R Murali; A Srinivasan
Journal:  J Virol       Date:  2000-11       Impact factor: 5.103

3.  The human immunodeficiency virus type 2 vpr gene is essential for productive infection of human macrophages.

Authors:  N Hattori; F Michaels; K Fargnoli; L Marcon; R C Gallo; G Franchini
Journal:  Proc Natl Acad Sci U S A       Date:  1990-10       Impact factor: 11.205

4.  Crystal structure of zinc-finger domain of Nanos and its functional implications.

Authors:  Hiroshi Hashimoto; Kodai Hara; Asami Hishiki; Shigeta Kawaguchi; Naoki Shichijo; Keishi Nakamura; Satoru Unzai; Yutaka Tamaru; Toshiyuki Shimizu; Mamoru Sato
Journal:  EMBO Rep       Date:  2010-10-15       Impact factor: 8.807

5.  Viral protein R of human immunodeficiency virus types 1 and 2 is dispensable for replication and cytopathogenicity in lymphoid cells.

Authors:  D Dedera; W Hu; N Vander Heyden; L Ratner
Journal:  J Virol       Date:  1989-07       Impact factor: 5.103

6.  Simian immunodeficiency virus Vpx is imported into the nucleus via importin alpha-dependent and -independent pathways.

Authors:  Prabhat K Singhal; P Rajendra Kumar; Malireddi R K Subba Rao; Mahesh Kyasani; Sundarasamy Mahalingam
Journal:  J Virol       Date:  2006-01       Impact factor: 5.103

7.  A leucine triplet repeat sequence (LXX)4 in p6gag is important for Vpr incorporation into human immunodeficiency virus type 1 particles.

Authors:  Y L Lu; R P Bennett; J W Wills; R Gorelick; L Ratner
Journal:  J Virol       Date:  1995-11       Impact factor: 5.103

8.  A virion-specific inhibitory molecule with therapeutic potential for human immunodeficiency virus type 1.

Authors:  Z Matsuda; X Yu; Q C Yu; T H Lee; M Essex
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

9.  The p6gag domain of human immunodeficiency virus type 1 is sufficient for the incorporation of Vpr into heterologous viral particles.

Authors:  E Kondo; F Mammano; E A Cohen; H G Göttlinger
Journal:  J Virol       Date:  1995-05       Impact factor: 5.103

Review 10.  Morphogenesis and morphology of HIV. Structure-function relations.

Authors:  H R Gelderblom; M Ozel; G Pauli
Journal:  Arch Virol       Date:  1989       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.